logo
Plus   Neg
Share
Email

Celgene Reveals Multiple Analyses Data Of Abraxane In Non-Small Cell Lung Cancer

Celgene International Sarl, a subsidiary of Celgene Corp. (CELG), Sunday revealed data from multiple presentations evaluating Abraxane in combination with carboplatin in patients with advanced non-small cell lung cancer.

The two reports presented data from retrospective analyses of CA-031, the phase III, multi-center, randomized study where patients received either nab-paclitaxel weekly plus carboplatin every three weeks or paclitaxel every three weeks plus carboplatin as first-line therapy for advanced non-small cell lung cancer.

Based on the data from CA-031, Celgene submitted an sNDA for Abraxane for the first-line treatment of patients with advanced non-small cell lung cancer with the U.S. Food and Drug Administration in December 2011. The current PDUFA (Prescription Drug User Fee Act) date for the submission is October 12, 2012.

Results of the study published on April 30, 2012 in the Journal of Clinical Oncology demonstrated a higher overall response rate, the approved primary end-point of the study based on a Special Protocol Assessment, for patients in the nab-paclitaxel arm compared to those in the paclitaxel arm.

The first sub-analysis evaluated elderly patients in the study and patients under 70. In both groups, overall response rate was higher in patients receiving nab-paclitaxel, though the difference was not significant in elderly patients between the arms of the study.

The second report evaluated patients with squamous-cell histology and non-squamous cell patients. The nab-paclitaxel arm demonstrated a significantly higher overall response rate and a slight improvement in overall survival, compared to the paclitaxel arm.

These results are from an investigational study and Abraxane is not indicated in the treatment of non-small cell lung cancer.

CELG traded on Friday at $65.33, down $2.92 or 4.28%, on a volume of 4.5 million shares on the Nasdaq.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
In a move likely to further inflame global trade tensions, President Donald Trump has threatened to impose a 20 percent tariff on all cars imported to the U.S. from the European Union. Trump claimed he would impose the new tariffs unless the EU removes tariffs and trade barriers placed on the U.S. The Federal Reserve has determined that the largest U.S. banks are strongly capitalized and would be able to lend to banks as well as households during a severe global economic recession. This is the fourth straight year that all banks have met the Federal Reserve's standards. The first round of results of the supervisory stress tests were released by the central bank on Thursday. The "safety" driver behind the wheel of a self-driving Uber was streaming a television show on her smartphone up until about the time of a fatal crash in March, according to a report from the Tempe Police Department. Uber's self-driving Volvo SUV, which was traveling at under 44 miles per hour, had struck and killed a pedestrian in Arizona on March 18.
Follow RTT